As Bayer Awaits a Landmark Supreme Court Ruling, a €5 Billion Legal Tab Looms for 2026

Bayer shares settle at €37.81, just above 50-day moving average. Key catalysts: US Supreme Court Roundup ruling, €5B cash outflows, US drug pricing probe, and Nubeqa patent fight.

Bayer’s stock settled at €37.81 on Friday, a level that coincides almost perfectly with its 50-day moving average of €37.80. The weekly gain of 4.85% came after the shares crossed above the 200-day moving average on June 17, building on a recovery of more than 50% from the 52-week low of €25.09. Still, the stock remains roughly 24% below its high of €49.93, reflecting deep uncertainty over a convergence of legal, regulatory and financial challenges.

The most immediate catalyst hangs over the company’s glyphosate liabilities. The U.S. Supreme Court is expected to rule before the end of June on the “Durnell” case from Missouri, which will decide whether federal law preempts state-level claims over warning labels on Roundup. A favorable judgment would give Bayer a powerful lever to slash the roughly $10 billion already spent on the litigation. The group proposed a $7.1 billion settlement in February; a Supreme Court win could dramatically reduce that overhang.

Yet any relief from the courts may be offset by a deepening cash crunch. Bayer expects legal outflows of about €5 billion in 2026 alone, pushing free cash flow as low as minus €2.5 billion. Net financial debt could climb to €33 billion by year-end. To counter the drain, management is counting on stronger revenue from the agriculture and consumer health segments rather than any quick fix from disposals.

The urgency to protect key profit pools is visible on multiple fronts. On Friday, the U.S. Trade Representative’s office, led by Ambassador Jamieson Greer, launched a formal investigation into German drug pricing policies, accusing American patients of shouldering a disproportionate share of global R&D costs. If the probe leads to sanctions, Bayer could face mandatory rebates or clawbacks in its largest market, squeezing margins in pharmaceuticals.

Meanwhile, the company is fighting to defend its prostate cancer drug Nubeqa, which generated $1.92 billion in revenue over the first nine months of 2025. Bayer filed an amended lawsuit on June 15 against Johnson & Johnson, alleging that J&J’s rival drug Erleada ($2.62 billion in sales) is marketed using a flawed real-world analysis. A federal judge in Manhattan refused to block those claims earlier, so Bayer is now seeking a permanent injunction and damages.

On the pipeline side, Bayer has completed the acquisition of Perfuse Therapeutics for an upfront payment of $300 million and potential milestone payments of up to $2.45 billion. The deal centers on PER-001, an intravitreal implant for glaucoma and diabetic retinopathy that is currently in Phase II trials. The drug will slot into Bayer’s existing ophthalmology portfolio.

There are also operational bright spots. Bayer’s new SOLIDA-1 production facility in Leverkusen has won two industry awards. The plant uses artificial intelligence to produce up to 1.2 billion tablets annually, a showcase of efficiency gains that could help offset margin pressure.

With the Supreme Court decision days away and the USTR investigation gathering pace, the next few weeks will determine whether the stock can push through resistance at the 52-week high or retreat. The next scheduled catalyst for fundamentals is the second-quarter earnings release on August 4, 2026 — by which time the legal landscape could look very different.